Skip to content
MARKETS / NASDAQ / MASS
NASDAQ · LABORATORY ANALYTICAL INSTRUMENTS · SMALL CAP

908 Devices Inc. MASS

6 fiscal years on record · USD · FY2025 reported · SEC filings only
$56.2M
▲ 17.7% YoY
$19.5M
$-24.6M
In brief

What this company does

The products referred to in the Business section are the MX908, ThreatID, ProtectIR, XplorIR, and VipIR. Since the launch of its first device in 2014, the company has sold more than 3,700 handheld devices to over 700 customers, including numerous domestic and foreign government agencies. As of December 31, 2025, the company had 172 full-time employees, of which 35 work in sales, sales support and marketing, 43 work in engineering and research and development, 62 work in manufacturing, operations and service and 32 work in general and administrative.

Written from the business description in 908 Devices Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 9 March 2026. Every sentence was checked against that document before publication.

Growth
USD 56.2M
Revenue, FY2025 · full 6-year series below
Revenue $M Net income $M
FY2025 · Revenue 56.2 · Net income 19.5
20.0M40.0M-25.0M-50.0M202020212022202320242025
Compound annual growth
+6.2%
+15.9%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +15.9% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
35 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating -70.1% · Net 34.7%
10%20%30%-50%-100%-150%202020212022202320242025
ROE
FY2025 · ROE 15.1%
5%10%15%-20%-40%202020212022202320242025

Each USD of equity produced 15 cents of profit this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -24.6
2M4M-20M202020212022202320242025

Total assetsUSD 190.1M
EquityUSD 143.7M
CashUSD 70.5M
Current ratio4.24×

Equity funds 76% of total assets.

The 6-year record
6 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020
Revenue $B0.10.00.10.00.00.0
Operating income $B−0.0−0.1−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.1−0.0−0.0−0.0−0.0
Income tax $B−0.0−0.0−0.00.0··
Net income $B0.0−0.1−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.00.0
EPS, diluted $0.54−2.12−1.13−1.07−0.79−2.35
Dividend / sh $······
Payout %······
ROE %15.1−51.6−20.4−16.6−12.5−9.2
Shares out B0.040.040.030.030.030.03

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 30 reconciliationsAUDITED

Reconciled in 6 of 19 fiscal years. 65 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityLaboratory Analytical Instruments
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2020

Share this section

Download image